Heron Therapeutics (HRTX) Tops Q3 EPS by 10c

Heron Therapeutics (NASDAQ: HRTX) reported Q3 EPS of ($0.51), $0.10 better than the analyst estimate of ($0.61). Revenue for the quarter came in at $23.2 million versus the consensus estimate of $25.51 million.

For earnings history and earnings-related data on Heron Therapeutics (HRTX) click here.

You May Also Be Interested In

• Citrini flags overheating concerns as leverage, chip rally weigh on KOSPI
• Deutsche Bank Starts Tandem Diabetes Care (TNDM) at Hold
• Synopsys upgraded at Piper Sandler on Intel foundry momentum, Apple opportunity